Lunit

Lunit Rule of 40

The Rule of 40 of Lunit (328130.KQ) as of Nov 6, 2026 is 75.60 %. In the previous year, Rule of 40 was 11.36 % — a change of 565.44% (higher).

Rule of 40

75.60 %

YoY

565.44%

Last updated:

Rule of 40 of Lunit is 2024 75.60 % . Rule of 40 of Lunit was 2023 11.36 % . It decreases by 565.44% higher compared to the previous year.

The Lunit Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2020
-844.25 KRW
Jan 1, 2021
-324.11 KRW
Jan 1, 2022
26.05 KRW
Jan 1, 2023
11.36 KRW
Jan 1, 2024
75.60 KRW
The Lunit Rule of 40 history
YEARRule of 40YoY
75.60 %+565.44%
11.36 %-56.38%
26.05 %-108.04%
-324.11 %-61.61%
-844.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Rule of 40 of Lunit is 75.60 % in 2024.

On Eulerpool you can find the complete historical development of Rule of 40 Lunit since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Lunit

All Key Metrics — Lunit